A Phase 2B Double-Blind Randomized Placebo-Controlled Multicenter Dose-Ranging Study to Evaluate the Efficacy and Safety Profile of PF-06700841 in Participants with Active Systemic Lupus Erythematosus (SLE)

Go Back to All Clinical Trials

A Phase 2B Double-Blind Randomized Placebo-Controlled Multicenter Dose-Ranging Study to Evaluate the Efficacy and Safety Profile of PF-06700841 in Participants with Active Systemic Lupus Erythematosus (SLE)

Brief description of study

The purpose of this study is to compare the effects of the study drug PF 06700841 tablets, at different doses with a placebo to find out which is better for Lupus. The study drug, PF 06700841, is an investigational drug because it is not approved for use in United States. The placebo looks like the study drug but does not contain any active ingredients. Researchers will compare the results of taking the placebo to the results of taking the study drug to see if there are any differences.

Clinical Study Identifier: s19-00644

ClinicalTrials.gov Identifier: NCT03845517

Clinical Research Studies

A Phase 2B Double-Blind Randomized Placebo-Controlled Multicenter Dose-Ranging Study to Evaluate the Efficacy and Safety Profile of PF-06700841 in Participants with Active Systemic Lupus Erythematosus (SLE)

Brief description of study

Recruitment Status

212-263-4432

646-754-7432